Efficacy and Tolerability Profile of Nebivolol vs Atenolol in Mild-to-moderate Essential Hypertension

Results of a Double-blind Randomized Multicentre Trial

Guido Grassi, Fosca Quarti Trevano, Annalisa Facchini, Torakis Toutouzas, Bernard Chanu, Giuseppe Mancia

Research output: Contribution to journalArticle

Abstract

The objective of this 12-week double-blind randomized multicentre study was to compare the efficacy and tolerability of nebivolol, a recently developed beta-blocking agent with vasodilating properties, to the classical beta-blocker atenolol. After a placebo run-in phase, 205 mild-to-moderate middle-age essential hypertensives were randomized to either nebivolol 5 mg daily (n = 105) or atenolol 100 mg daily (n = 100) over a period of 12 weeks. The primary endpoint of the study was the change in sitting systolic and diastolic blood pressure (SBP and DBP respectively) from baseline to week 12 of treatment. The two drugs induced similar significant antihypertensive effects, the SBP and DBP reduction amounting to- 18.2 ± 14.0 and-14.6 ± 7.9 mmHg (mean ± SD) for atenolol and -19.1 ± 12.9 and -14.8 ± 7.1 for nebivolol (p <0.01 for all). This was the case also for standing blood pressure. Sitting and standing heart rate values were significantly reduced by both drugs, the bradicardic response induced by nebivolol treatment being significantly less than atenolol. Distribution of responders and non- responders was similar for nebivolol and atenolol, while the former drug showed a better tolerability profile and a lower incidence of side-effects. These data provide evidence, that, for the same antihypertensive effects, nebivolol shows a better tolerability profile than atenolol and a lower incidence of adverse effects.

Original languageEnglish
Pages (from-to)35-40
Number of pages6
JournalBlood Pressure, Supplement
Volume12
Issue number2
Publication statusPublished - Dec 2003

Fingerprint

Nebivolol
Atenolol
Multicenter Studies
Blood Pressure
Antihypertensive Agents
Pharmaceutical Preparations
Incidence
Essential Hypertension
Heart Rate
Placebos

Keywords

  • Atenolol
  • Clinical trials
  • Essential hypertension
  • Nebivolol
  • Tolerability

ASJC Scopus subject areas

  • Internal Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Efficacy and Tolerability Profile of Nebivolol vs Atenolol in Mild-to-moderate Essential Hypertension : Results of a Double-blind Randomized Multicentre Trial. / Grassi, Guido; Trevano, Fosca Quarti; Facchini, Annalisa; Toutouzas, Torakis; Chanu, Bernard; Mancia, Giuseppe.

In: Blood Pressure, Supplement, Vol. 12, No. 2, 12.2003, p. 35-40.

Research output: Contribution to journalArticle

Grassi, Guido ; Trevano, Fosca Quarti ; Facchini, Annalisa ; Toutouzas, Torakis ; Chanu, Bernard ; Mancia, Giuseppe. / Efficacy and Tolerability Profile of Nebivolol vs Atenolol in Mild-to-moderate Essential Hypertension : Results of a Double-blind Randomized Multicentre Trial. In: Blood Pressure, Supplement. 2003 ; Vol. 12, No. 2. pp. 35-40.
@article{2d5eb666829b4e11977115838492c12e,
title = "Efficacy and Tolerability Profile of Nebivolol vs Atenolol in Mild-to-moderate Essential Hypertension: Results of a Double-blind Randomized Multicentre Trial",
abstract = "The objective of this 12-week double-blind randomized multicentre study was to compare the efficacy and tolerability of nebivolol, a recently developed beta-blocking agent with vasodilating properties, to the classical beta-blocker atenolol. After a placebo run-in phase, 205 mild-to-moderate middle-age essential hypertensives were randomized to either nebivolol 5 mg daily (n = 105) or atenolol 100 mg daily (n = 100) over a period of 12 weeks. The primary endpoint of the study was the change in sitting systolic and diastolic blood pressure (SBP and DBP respectively) from baseline to week 12 of treatment. The two drugs induced similar significant antihypertensive effects, the SBP and DBP reduction amounting to- 18.2 ± 14.0 and-14.6 ± 7.9 mmHg (mean ± SD) for atenolol and -19.1 ± 12.9 and -14.8 ± 7.1 for nebivolol (p <0.01 for all). This was the case also for standing blood pressure. Sitting and standing heart rate values were significantly reduced by both drugs, the bradicardic response induced by nebivolol treatment being significantly less than atenolol. Distribution of responders and non- responders was similar for nebivolol and atenolol, while the former drug showed a better tolerability profile and a lower incidence of side-effects. These data provide evidence, that, for the same antihypertensive effects, nebivolol shows a better tolerability profile than atenolol and a lower incidence of adverse effects.",
keywords = "Atenolol, Clinical trials, Essential hypertension, Nebivolol, Tolerability",
author = "Guido Grassi and Trevano, {Fosca Quarti} and Annalisa Facchini and Torakis Toutouzas and Bernard Chanu and Giuseppe Mancia",
year = "2003",
month = "12",
language = "English",
volume = "12",
pages = "35--40",
journal = "Blood Pressure, Supplement",
issn = "0803-8023",
publisher = "Taylor and Francis Ltd.",
number = "2",

}

TY - JOUR

T1 - Efficacy and Tolerability Profile of Nebivolol vs Atenolol in Mild-to-moderate Essential Hypertension

T2 - Results of a Double-blind Randomized Multicentre Trial

AU - Grassi, Guido

AU - Trevano, Fosca Quarti

AU - Facchini, Annalisa

AU - Toutouzas, Torakis

AU - Chanu, Bernard

AU - Mancia, Giuseppe

PY - 2003/12

Y1 - 2003/12

N2 - The objective of this 12-week double-blind randomized multicentre study was to compare the efficacy and tolerability of nebivolol, a recently developed beta-blocking agent with vasodilating properties, to the classical beta-blocker atenolol. After a placebo run-in phase, 205 mild-to-moderate middle-age essential hypertensives were randomized to either nebivolol 5 mg daily (n = 105) or atenolol 100 mg daily (n = 100) over a period of 12 weeks. The primary endpoint of the study was the change in sitting systolic and diastolic blood pressure (SBP and DBP respectively) from baseline to week 12 of treatment. The two drugs induced similar significant antihypertensive effects, the SBP and DBP reduction amounting to- 18.2 ± 14.0 and-14.6 ± 7.9 mmHg (mean ± SD) for atenolol and -19.1 ± 12.9 and -14.8 ± 7.1 for nebivolol (p <0.01 for all). This was the case also for standing blood pressure. Sitting and standing heart rate values were significantly reduced by both drugs, the bradicardic response induced by nebivolol treatment being significantly less than atenolol. Distribution of responders and non- responders was similar for nebivolol and atenolol, while the former drug showed a better tolerability profile and a lower incidence of side-effects. These data provide evidence, that, for the same antihypertensive effects, nebivolol shows a better tolerability profile than atenolol and a lower incidence of adverse effects.

AB - The objective of this 12-week double-blind randomized multicentre study was to compare the efficacy and tolerability of nebivolol, a recently developed beta-blocking agent with vasodilating properties, to the classical beta-blocker atenolol. After a placebo run-in phase, 205 mild-to-moderate middle-age essential hypertensives were randomized to either nebivolol 5 mg daily (n = 105) or atenolol 100 mg daily (n = 100) over a period of 12 weeks. The primary endpoint of the study was the change in sitting systolic and diastolic blood pressure (SBP and DBP respectively) from baseline to week 12 of treatment. The two drugs induced similar significant antihypertensive effects, the SBP and DBP reduction amounting to- 18.2 ± 14.0 and-14.6 ± 7.9 mmHg (mean ± SD) for atenolol and -19.1 ± 12.9 and -14.8 ± 7.1 for nebivolol (p <0.01 for all). This was the case also for standing blood pressure. Sitting and standing heart rate values were significantly reduced by both drugs, the bradicardic response induced by nebivolol treatment being significantly less than atenolol. Distribution of responders and non- responders was similar for nebivolol and atenolol, while the former drug showed a better tolerability profile and a lower incidence of side-effects. These data provide evidence, that, for the same antihypertensive effects, nebivolol shows a better tolerability profile than atenolol and a lower incidence of adverse effects.

KW - Atenolol

KW - Clinical trials

KW - Essential hypertension

KW - Nebivolol

KW - Tolerability

UR - http://www.scopus.com/inward/record.url?scp=1642471654&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1642471654&partnerID=8YFLogxK

M3 - Article

VL - 12

SP - 35

EP - 40

JO - Blood Pressure, Supplement

JF - Blood Pressure, Supplement

SN - 0803-8023

IS - 2

ER -